Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) – Analysts at SunTrust Banks raised their FY2018 earnings per share estimates for Ariad Pharmaceuticals in a report released on Thursday. SunTrust Banks analyst Y. Suneja now expects that the brokerage will post earnings per share of $0.65 for the year, up from their previous estimate of $0.58. SunTrust Banks has a “Buy” rating on the stock. SunTrust Banks also issued estimates for Ariad Pharmaceuticals’ FY2020 earnings at $2.10 EPS.

ARIA has been the subject of a number of other research reports. Jefferies Group restated a “buy” rating and set a $13.00 target price on shares of Ariad Pharmaceuticals in a research note on Wednesday, June 22nd. Zacks Investment Research cut shares of Ariad Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, July 8th. Leerink Swann assumed coverage on shares of Ariad Pharmaceuticals in a research note on Monday, September 26th. They set an “outperform” rating for the company. Cowen and Company restated an “outperform” rating and set a $10.00 target price on shares of Ariad Pharmaceuticals in a research note on Sunday, July 31st. Finally, Royal Bank Of Canada restated a “hold” rating on shares of Ariad Pharmaceuticals in a research note on Monday, June 20th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $11.89.

Earnings History and Estimates for Ariad Pharmaceuticals (NASDAQ:ARIA)

Ariad Pharmaceuticals (NASDAQ:ARIA) opened at 11.14 on Friday. The firm has a 50-day moving average of $12.18 and a 200-day moving average of $9.04. Ariad Pharmaceuticals has a 52-week low of $4.37 and a 52-week high of $14.34. The firm’s market capitalization is $2.15 billion.

Ariad Pharmaceuticals (NASDAQ:ARIA) last released its quarterly earnings results on Thursday, July 28th. The pharmaceutical company reported $0.59 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.11) by $0.70. The firm earned $65.30 million during the quarter, compared to analyst estimates of $60.64 million. Ariad Pharmaceuticals’s quarterly revenue was up 133.0% on a year-over-year basis. During the same quarter last year, the firm earned ($0.28) earnings per share.

In other Ariad Pharmaceuticals news, insider Timothy P. Clackson sold 18,286 shares of the firm’s stock in a transaction dated Friday, July 22nd. The shares were sold at an average price of $8.11, for a total value of $148,299.46. Following the transaction, the insider now directly owns 248,208 shares of the company’s stock, valued at approximately $2,012,966.88. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Timothy P. Clackson sold 8,750 shares of the firm’s stock in a transaction dated Wednesday, September 28th. The shares were sold at an average price of $13.98, for a total transaction of $122,325.00. Following the completion of the transaction, the insider now directly owns 226,272 shares in the company, valued at $3,163,282.56. The disclosure for this sale can be found here. 8.20% of the stock is currently owned by company insiders.

A number of institutional investors have recently added to or reduced their stakes in the stock. Ameritas Investment Partners Inc. raised its position in Ariad Pharmaceuticals by 6.7% in the second quarter. Ameritas Investment Partners Inc. now owns 13,787 shares of the pharmaceutical company’s stock valued at $102,000 after buying an additional 866 shares in the last quarter. Teacher Retirement System of Texas increased its stake in Ariad Pharmaceuticals by 4.7% in the second quarter. Teacher Retirement System of Texas now owns 23,057 shares of the pharmaceutical company’s stock worth $170,000 after buying an additional 1,027 shares during the last quarter. Amalgamated Bank increased its stake in Ariad Pharmaceuticals by 6.5% in the second quarter. Amalgamated Bank now owns 18,729 shares of the pharmaceutical company’s stock worth $190,000 after buying an additional 1,135 shares during the last quarter. Family Management Corp increased its stake in Ariad Pharmaceuticals by 0.7% in the second quarter. Family Management Corp now owns 179,515 shares of the pharmaceutical company’s stock worth $1,327,000 after buying an additional 1,250 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System increased its stake in Ariad Pharmaceuticals by 0.9% in the second quarter. State Board of Administration of Florida Retirement System now owns 137,570 shares of the pharmaceutical company’s stock worth $1,017,000 after buying an additional 1,270 shares during the last quarter. 71.99% of the stock is currently owned by hedge funds and other institutional investors.

About Ariad Pharmaceuticals

ARIAD Pharmaceuticals, Inc (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company’s product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company’s Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

5 Day Chart for NASDAQ:ARIA

Receive News & Stock Ratings for Ariad Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ariad Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.